HALO insider buying and SEC filings, explained
Halozyme Therapeutics, Inc. · CIK 1159036
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$599K
Planned sales (10b5-1)
$46.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 6–8, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 60,000 shares between Oct 6 and Oct 8 at about $110.18 ($6.6M), marked as a 10b5-1 plan trade. Holdings down 7% to 767,780 shares. | SEC filing Filed Oct 8, 2026, 7:56 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Matthew L. Posard (Director) sold 5,230 shares at about $108.54 ($568K), marked as a 10b5-1 plan trade. Holdings down 9% to 53,609 shares. | SEC filing Filed Oct 2, 2026, 4:38 PM ET |
| Sep 16, 2026 | Planned (10b5-1) | Matthew L. Posard (Director) sold 18,996 shares at about $107.74 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 24% to 58,839 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 9–11, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 60,000 shares between Sep 9 and Sep 11 at about $107.28 ($6.4M), marked as a 10b5-1 plan trade. Holdings down 7% to 767,780 shares. | SEC filing Filed Sep 11, 2026 |
| Aug 17–19, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 60,000 shares between Aug 17 and Aug 19 at about $104.59 ($6.3M), marked as a 10b5-1 plan trade. Holdings down 7% to 767,780 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 1,626 shares at $102.80 ($167K), marked as a 10b5-1 plan trade. Holdings down 4% to 40,418 shares. | SEC filing Filed Aug 11, 2026 |
| Jul 8, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 1,923 shares at about $79.77 ($153K), marked as a 10b5-1 plan trade. Holdings down <1% to 767,780 shares. | SEC filing Filed Jul 9, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 1,625 shares at about $76.71 ($125K), marked as a 10b5-1 plan trade. Holdings down 4% to 42,044 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Mahesh Krishnan (Director) sold 7,304 shares at $75.00 ($548K), marked as a 10b5-1 plan trade. Holdings down 34% to 14,462 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 1–3, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 50,000 shares between Jun 1 and Jun 3 at about $67.40 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 6% to 767,780 shares. | SEC filing Filed Jun 3, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 1,625 shares at $66.21 ($108K), marked as a 10b5-1 plan trade. Holdings down 4% to 43,669 shares. | SEC filing Filed Jun 2, 2026 |
| May 11–13, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 50,000 shares between May 11 and May 13 at about $68.68 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 6% to 767,780 shares. | SEC filing Filed May 13, 2026 |
| May 1, 2026 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 1,625 shares at $63.48 ($103K), marked as a 10b5-1 plan trade. Holdings down 4% to 38,498 shares. | SEC filing Filed May 5, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 10,000 shares at about $63.50 ($635K), marked as a 10b5-1 plan trade. Holdings down 1% to 767,780 shares. | SEC filing Filed Apr 7, 2026 |
| Apr 1–2, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 40,000 shares between Apr 1 and Apr 2 at about $64.81 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 5% to 767,780 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 10, 2026 | Sale | Cortney Caudill (President / COO) sold 8,857 shares at about $67.64 ($599K). Holdings down 56% to 7,055 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Mar 2–4, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 50,000 shares between Mar 2 and Mar 4 at about $69.52 ($3.5M), marked as a 10b5-1 plan trade. Holdings down 6% to 767,780 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 3–5, 2026 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 50,000 shares between Feb 3 and Feb 5 at about $77.07 ($3.9M), marked as a 10b5-1 plan trade. Holdings down 7% to 708,719 shares. | SEC filing Filed Feb 5, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 2,000 shares at $70.25 ($141K), marked as a 10b5-1 plan trade. Holdings down 5% to 40,123 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 1, 2025 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 829 shares at $71.60 ($59K), marked as a 10b5-1 plan trade. Holdings down 2% to 42,123 shares. | SEC filing Filed Dec 1, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 16,569 shares at about $68.92 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 2% to 708,719 shares. | SEC filing Filed Dec 1, 2025 |
| Nov 10–12, 2025 | Planned (10b5-1) | Helen Torley (CEO and Director) sold 60,000 shares between Nov 10, 2025 and Nov 12, 2025 at about $69.46 ($4.2M), marked as a 10b5-1 plan trade. Holdings down 8% to 733,719 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Bernadette Connaughton (Director) sold 2,000 shares at $68.48 ($137K), marked as a 10b5-1 plan trade. Holdings down 4% to 42,952 shares. | SEC filing Filed Nov 12, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow HALO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.